Abstract:Objective To evaluate clinical, pathological and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-enhanced MRI) findings of hepatocellular carcinoma (HCC) in non-cirrhotic livers and compare with HCC in cirrhotic livers. Methods This retrospective study included patients with pathologically confirmed HCC who underwent preoperative Gd-EOB-DTPA-enhanced MRI between January 2015 and October 2021. Propensity scores were utilized to match non-cirrhotic HCCs (NCHCCs) patients with cirrhotic HCCs (CHCCs) patients. The clinical, pathological and MR imaging features of NCHCCs were compared with CHCCs. Correlation between these features and the presence of NCHCCs were analyzed by logistic regression analysis. The predictive efficacy was evaluated using receiver operating characteristic (ROC) analysis. The area under the receiver operating characteristic curve (AUC) was used to compare performance, and the Delong test was used to compare AUCs. Results After propensity score matching (1:3), a total of 144 patients with HCCs (36 NCHCCs and 108 CHCCs) were included. NCHCCs were larger in tumor size than CHCCs ( P < 0.001, Cohen's d = 0.737). NCHCCs were more common in patients who have hepatitis C (5.6 % vs 1.9 %, P > 0.05) or have no known liver disease (11.1 % vs 0.9 %, P = 0.004), while hepatitis B was more common in CHCC patients (83.3 % vs 97.2 %, P = 0.003). Compared with CHCCs, NCHCCs more frequently demonstrated non-smooth tumor margin ( P = 0.001, Cramer's V = 0.273), peri-tumoral hyperintensity ( P < 0.05, Cramer's V = 0.185), hyperintense and heterogeneous signals in hepatobiliary phase (HBP) ( P < 0.05). CHCCs were more likely to have satellite nodules compared to NCHCCs (33.3 % vs 57.4 %, P < 0.05, Cramer's V = 0.209). Based on the univariate and multivariate logistic regression analysis, the tumor size, non-smooth tumor margin, heterogeneous intensity in HBP and satellite nodule were significantly correlated to NCHCCs ( P all <0.05). ROC curve analysis demonstrated that tumor size and non-smooth tumor margin were potential imaging predictors for the diagnosis of NCHCC, with AUC values of 0.715 and 0.639, respectively. The combination of the two imaging features for identifying NCHCC achieved an AUC value of 0.761, with a sensitivity of 0.889 and a specificity of 0.630. Conclusion NCHCCs were more likely to show larger tumor size, non-smooth tumor margin, peri-tumoral hyperintensity, as well as hyperintense and heterogeneous signals in HBP at Gd-EOB-DTPA-enhanced MR imaging compared with NCHCCs. Tumor size and non-smooth tumor margin in HBP may help to discriminate NCHCCs.

Imaging Features of Hepatocellular Carcinoma: Quantitative and Qualitative Comparison Between MRI-Enhanced With Gd-EOB-DTPA and Gd-DTPA

Contrast-enhanced Multiple-Phase Imaging Features of Intrahepatic Mass-Forming Cholangiocarcinoma and Hepatocellular Carcinoma with Cirrhosis: A Comparative Study

Contrast-Enhanced Multiple-Phase Imaging Features in Hepatic Epithelioid Hemangioendothelioma

A Compared Study on Gd+-EOB-DTPA and Gd+-DTPA-enhanced MRI in Detection of Hepatocellular Carcinoma

Imaging Features Of Intrahepatic Mass-Forming Cholangiocarcinomas On Gd-Bopta-Enhanced Mri

Comparison of the Ability of Gadobenate Dimeglumine and Gadolinium Ethoxybenzyl Dimeglumine to Display the major Features for Noninvasively Diagnosing Hepatocellular Carcinoma According to the LI-RADS 2018v

Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy

Comparative the Clinical Value of Contrast-Enhanced Ultrasonography, Enhancement CT and MRI for Diagnosing of Liver Lesions.

The Value of Contrast-Enhanced Magnetic Resonance Imaging Enhancement in the Differential Diagnosis of Hepatocellular Carcinoma and Combined Hepatocellular Cholangiocarinoma

Contrast-enhanced Computed Tomography Plus Gadolinium-Ethoxybenzyl Diethylenetriamine Pentaacetic Acid-Enhanced Magnetic Resonance Imaging for Gross Classification of Hepatocellular Carcinoma.

Study of Clinical Application of Hepatic-Biliary Specific MR Contrast Agent(gd-Eob-dtpa) in the Diagnosis of Focal Hepatic Lesions

Gd-EOB-DTPA-enhanced MR imaging features of hepatocellular carcinoma in non-cirrhotic liver

Comparison of Sonazoid-Contrast‑Enhanced Ultrasound and Gd‑EOB‑DTPA‑Enhanced MRI for Predicting Microvascular Invasion in Hepatocellular Carcinoma

Additional Value of 10-Min Far-Delayed Phase in Extracellular Contrast Agent-Enhanced MRI for Diagnostic Performance of Hepatocellular Carcinoma Based on LI-RADS V2018

[Small Hepatocellular Carcinoma in Patients with Hepatitis B-induced Cirrhosis: a Comparison Between MRI and MDCT].

Hepatocellular carcinoma 20 mm or smaller in cirrhosis patients: early magnetic resonance enhancement by gadoxetic acid compared with gadopentetate dimeglumine

Magnetic Resonance Imaging for Colorectal Cancer Metastasis to the Liver: Comparative Effectiveness Research for the Choice of Contrast Agents

Washout appearance in Gd-EOB-DTPA-enhanced MR imaging: A differentiating feature between hepatocellular carcinoma with paradoxical uptake on the hepatobiliary phase and focal nodular hyperplasia-like nodules

Intraindividual comparison of prognostic imaging features of HCCs between MRIs with extracellular and hepatobiliary contrast agents

HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI

Comparison of Gadoxetic Acid Versus Gadopentetate Dimeglumine for the Detection of Hepatocellular Carcinoma at 1.5 T Using the Liver Imaging Reporting and Data System (LI-RADS V.2017)